Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity
Purpose: To evaluate the outcome and ocular adverse events of bedside bilateral sequential intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity (ROP) (BBSIR). Methods: This retrospective interventional study included infants who received BBSIR with a follow-...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/IJO.IJO_558_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556776228487168 |
|---|---|
| author | Priya Bajgai Susree Satavisa Taraprasad Das Subhadra Jalali Balakrushna Samanataray Sameera Nayak Tapas Ranjan Padhi |
| author_facet | Priya Bajgai Susree Satavisa Taraprasad Das Subhadra Jalali Balakrushna Samanataray Sameera Nayak Tapas Ranjan Padhi |
| author_sort | Priya Bajgai |
| collection | DOAJ |
| description | Purpose:
To evaluate the outcome and ocular adverse events of bedside bilateral sequential intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity (ROP) (BBSIR).
Methods:
This retrospective interventional study included infants who received BBSIR with a follow-up of at least 1 month. Clinical history, intravitreal injection details, indications, intraoperative and postoperative ocular adverse events, and outcomes were analyzed.
Results:
The study cohort included 192 babies (384 eyes) spread over 9 years. The mean gestational age was 30.2 ± 2.6 weeks (28.8–34.1), and the birth weight was 1098.11 ± 271.65 g (650–2000). The indications for BBSIR were as follows: 73.4% (n = 141 infants) were too sick to transfer to an ophthalmic unit, 10.9% (n = 21 infants) due to the parents’ inconvenience of traveling to the ophthalmic center, and 15. 6% (n = 30 infants) due to both reasons. The injections were given by an ROP specialist/ROP-trained ophthalmologist after due parental consent, considering each eye as a fresh eye with separate scrubbing and draping. Light from the head-worn indirect ophthalmoscope served as the source of illumination. The retinopathy was regressing/regressed in 92.4% of babies until the last follow-up. The major ocular complication was cataract in 2 eyes (0.5%). There was no incidence of endophthalmitis till last follow-up (median 5.7 months).
Conclusions:
As per this study, BBSIR was observed to be effective and safe if given by those fully trained in the management of ROP. Though the rate of complications like cataract is small, they can pose management challenges and impact vision in a growing child. |
| format | Article |
| id | doaj-art-2a04f74e06ba4213800c90e5312e1f8c |
| institution | Kabale University |
| issn | 0301-4738 1998-3689 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj-art-2a04f74e06ba4213800c90e5312e1f8c2025-01-07T06:28:38ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892025-01-0173Suppl 1S112S11810.4103/IJO.IJO_558_24Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurityPriya BajgaiSusree SatavisaTaraprasad DasSubhadra JalaliBalakrushna SamanataraySameera NayakTapas Ranjan PadhiPurpose: To evaluate the outcome and ocular adverse events of bedside bilateral sequential intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity (ROP) (BBSIR). Methods: This retrospective interventional study included infants who received BBSIR with a follow-up of at least 1 month. Clinical history, intravitreal injection details, indications, intraoperative and postoperative ocular adverse events, and outcomes were analyzed. Results: The study cohort included 192 babies (384 eyes) spread over 9 years. The mean gestational age was 30.2 ± 2.6 weeks (28.8–34.1), and the birth weight was 1098.11 ± 271.65 g (650–2000). The indications for BBSIR were as follows: 73.4% (n = 141 infants) were too sick to transfer to an ophthalmic unit, 10.9% (n = 21 infants) due to the parents’ inconvenience of traveling to the ophthalmic center, and 15. 6% (n = 30 infants) due to both reasons. The injections were given by an ROP specialist/ROP-trained ophthalmologist after due parental consent, considering each eye as a fresh eye with separate scrubbing and draping. Light from the head-worn indirect ophthalmoscope served as the source of illumination. The retinopathy was regressing/regressed in 92.4% of babies until the last follow-up. The major ocular complication was cataract in 2 eyes (0.5%). There was no incidence of endophthalmitis till last follow-up (median 5.7 months). Conclusions: As per this study, BBSIR was observed to be effective and safe if given by those fully trained in the management of ROP. Though the rate of complications like cataract is small, they can pose management challenges and impact vision in a growing child.https://journals.lww.com/10.4103/IJO.IJO_558_24anti-vascular endothelial growth factorbedside injectionbilateral injectionsintravitreal injectionretinopathy of prematurity (rop) |
| spellingShingle | Priya Bajgai Susree Satavisa Taraprasad Das Subhadra Jalali Balakrushna Samanataray Sameera Nayak Tapas Ranjan Padhi Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity Indian Journal of Ophthalmology anti-vascular endothelial growth factor bedside injection bilateral injections intravitreal injection retinopathy of prematurity (rop) |
| title | Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity |
| title_full | Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity |
| title_fullStr | Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity |
| title_full_unstemmed | Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity |
| title_short | Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity |
| title_sort | bedside bilateral sequential intravitreal anti vegf injections for retinopathy of prematurity |
| topic | anti-vascular endothelial growth factor bedside injection bilateral injections intravitreal injection retinopathy of prematurity (rop) |
| url | https://journals.lww.com/10.4103/IJO.IJO_558_24 |
| work_keys_str_mv | AT priyabajgai bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity AT susreesatavisa bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity AT taraprasaddas bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity AT subhadrajalali bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity AT balakrushnasamanataray bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity AT sameeranayak bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity AT tapasranjanpadhi bedsidebilateralsequentialintravitrealantivegfinjectionsforretinopathyofprematurity |